Events

Translate this page RSS Share this page Print this page

SEARCH CRITERIA

DATE RANGE
to
 
A Cancer Moonshot and So Much More: An Introduction to the 21st Century Cures Act for Healthcare Providers and Pharmaceutical and Medical Device Companies


12 Jan 2017, 1:00 PM - 2:30 PM (Eastern Time)                            
ROUNDTABLE

Join us for a lively discussion about the 21st Century Cures Act, an expansive law that encompasses major reforms, funding, and regulatory changes of significant interest to healthcare providers and pharmaceutical and medical device manufacturers. Our program will bring you quickly up to speed on the key provisions of the bill, including insights regarding opportunities and challenges and why some of the innovations are controversial. We will address:

  • A brief overview of the legislative history and reasons for bipartisan support, including the provision over ten years of $4.8 billion to the NIH to support initiatives in precision medicine, the "cancer moonshot," the BRAIN initiative, and regenerative medicine, as well as over $500 million to FDA.
  • The provision of over $1 billion over two years in grants available to states to prevent and treat opioid abuse and enhance mental health services, and how healthcare providers face new opportunities and risks as a result.
  • Major reforms in federally-regulated clinical investigations and protection of human subjects, including, among other things, informed consent, the collection of patient experience data and "real world evidence" to support drug development, compassionate use policies for investigational drugs, and IRB requirements for medical device trials.
  • A streamlined FDA approval process, with provisions related to increased patient involvement in the drug approval process, biomarkers, accelerated approval for regenerative therapeutic products, expedited approval for breakthrough medical devices, and many other new developments. We will also discuss reforms regarding the provision of healthcare economic information (HCEI) to payors.
  • Key reforms in Medicare Part A and Part B that will affect healthcare providers, including changes to the CMS Hospital Readmission Reduction Program and immediate changes in the methodology for calculation of Medicare payments for Part B infused drugs. We will also briefly address reforms relating to hospital outpatient departments , telemedicine, and long-term care hospitals.

We plan a future webinar that will focus on the reforms in the new law that will affect electronic medical records and compliance with HIPAA.

You do not have to be a client to attend, and there is no charge.

You can register to attend this webinar by clicking the Register link at the bottom of this page.

General information on our practice is available in our electronic publications Serving the Healthcare Industry, Around the Corner and Serving the Life Sciences Industry. If you would like to be included on our regular pharmaceutical manufacturers, medical device manufacturers or healthcare provider mailing lists to receive notices of other events and written updates, you can be added by submitting your full contact information to lifesciences-healthcare@kslaw.com and specifying the list you wish to join.

You can also follow us on Twitter or Facebook.

Questions

If you have questions concerning this Roundtable Webinar, e-mail lifesciences-healthcare@kslaw.com.

PEOPLE